These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching. Mack GS J Natl Cancer Inst; 2006 Aug; 98(15):1028-30. PubMed ID: 16882935 [No Abstract] [Full Text] [Related]
3. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech. Garber K Science; 2006 May; 312(5775):827. PubMed ID: 16690824 [No Abstract] [Full Text] [Related]
4. Ariad's NFkappaB patent claims shot down on appeal. Garber K Nat Biotechnol; 2009 Jun; 27(6):494-5. PubMed ID: 19513036 [No Abstract] [Full Text] [Related]
5. Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement. Jakas J Seton Hall Law Rev; 2012; 42(3):1287-36. PubMed ID: 22803220 [No Abstract] [Full Text] [Related]
7. US courts struggle with new patent infringement standards. Jones P Nat Biotechnol; 2004 Apr; 22(4):461-3. PubMed ID: 15085803 [No Abstract] [Full Text] [Related]
8. Court upholds infringement of research tool patents, but discounts damages. Maebius SB; Warburg RJ Pharmacogenomics; 2003 Jul; 4(4):369-70. PubMed ID: 12831314 [No Abstract] [Full Text] [Related]
11. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
12. Patent fight sparks biological warfare in the drug industry. Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662 [No Abstract] [Full Text] [Related]
13. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape. Lu DL; Kowalski TJ; Jarecki-Black J Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040 [No Abstract] [Full Text] [Related]
14. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
16. Proposed changes to patent code loom over biotech industry. Coombs A Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010 [No Abstract] [Full Text] [Related]
17. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1). Tsao R; Hurley EA Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112 [No Abstract] [Full Text] [Related]
19. The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry. Burton CA; Margonis LE Pharm Pat Anal; 2013 Mar; 2(2):177-80. PubMed ID: 24237023 [No Abstract] [Full Text] [Related]
20. Patent watch: Progress in three key patent disputes in 2009. Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395 [No Abstract] [Full Text] [Related] [Next] [New Search]